Mpro paper in Science from Pfizer

“Researchers report the discovery of PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a key viral target. In a phase I clinical trial, it achieved concentrations expected to inhibit the virus based on in vitro studies”